pK papers
|
Title |
Authors |
| Bone penetration of intravenous flucloxacillin and gentamicin as antibiotic prophylaxis during total hip and knee arthroplasty. | Torkington MS, Davison MJ, Wheelwright EF, Jenkins PJ, Anthony I, Lovering AM, Blyth M, Jones B. Bone Joint J. 2017 Mar;99-B(3):358-364 |
| Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy. | Reeves D, Lovering A, Thomson A. J Antimicrob Chemother. 2016 Dec;71(12):3330-3332 |
| Amikacin use and therapeutic durg monitoring in adults: do dose regimens and drug exposures affect ither outcome or advers events? A systematic review | Jenkins, A, Thomson AH, Brown NM, Semple Y, Sluman C, Macgowan A, Lovering AM, Wiffen PJ; (BSAC Working Party on Therapeutic Drug Monitoring) J Antimicrob Chemother. 2016 Jul 11 |
| A review of the pharmacokinetics and pharmacodynamics of aztreonam | Ramsey C, MacGowan AP J Antimicrob Chemother. 2016 June 21 |
| Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection | Bowker KE, Noel AR, Tomaselli S, MacGowan AP J Antimicrob Chemother. 2016 May;71(5):1270-8 |
| The three wise monkeys of therapeutic drug monitoring. | AM Lovering, T Elston. www.rcpath.org.uk April 2016 Issue 174 |
| The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriacese in in vitro pharmacokenetic/pharmacodynamic model experiments | Albur MS, Noel A, Bowker K, MacGowan A. Int J Antimicrob Agents. 2015 Nov;46(5):560-7 |
| Pharmacodynamics of Ceftolozane plus Tazobactam studied in an in vitro Pharmacokinetic model of infection | MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21 |
| Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia | Mpenge MA, MacGowan AP Ther Clin Risk Manag. 2015 Apr 7;11:565-79 |
| Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection | MacGown AP, Noel AR, Tomaselli S, Bowker KE Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6 |
| Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum | Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP J Antimicrob Chemother. 2013 May;68(5):1130-8 |
| Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model | Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15 |
| Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriacese | Albur M, Moel A, Bowker K, MacGowan A Antimicrob Agents Chemother. 2012 Jun;56(6):3441-3 |
| The role of pharmacokinetics/pharmacodynamics in setting clincial MIC breakpionts: the EUCAST approach | Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, Macgowan AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G Clin Microbiol Infect. 2012 Mar;18(3):E37-45 |
| Role of early intravenos to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two- stage relacement | Darley ES, Bannister GC, Blom AW, MacGowan AP, Jacobsen SK, Alfouzan W J Antimicrob Chemother 2011 Oct;66(10):2405-8 |
| Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection | MacGown AP, Noel A, Tomaselli S, Elliott H, Bowker K. Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42 |
| Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection | MAcGowan AP, Noel A, Tomaselli S, Elliott H, Bowker KE. Antimicrob Agents Chemother. 2011 Feb;55(2):867-73 |
| Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service | Tobin CM, Lovering AM, Sweeney E, MacGowan AP J Antimicrob Chemother 2010 Oct;65(10):2155-7 |
| Pharmacokinetic evaluation of linezolid in patients with major thermal injuries | Le Floch R, Amould JF, Vinsonneau C, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Lovering AM Pathol Biol (Paris) 2010 Apr;58(2):e27-31 |
| Daptomycin in synovial fluid during treatment of methicillin-resistant Staphylococcus aureus septic arthritis | Ritchie ND, Lovering AM, Seaton RA J Antimicrob Chemother 2010 Jun;65(6): 1314-5 |
| Potentially dangerous misuse of the Hartford once-daily nomogram for gentamicin | Lovering AM, Reeves DS J Antimicrob Chemother 2009 Nov;64(5): 1117-8 |
| Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea | Kaye SB, Neal T, Nicholson S, Szkurlat J, Bamber S, Baddon AC, Anderson S, Seddon K, Dwyer N, Lovering AM, Smith G Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3176-84 |
| Pharmacokinetic evaluation of linezolid in patients with major thermal injuries | Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau CJ Antimicrob Chemother 2009 Mar;63(3):553-9 |
| Potentially dangerous use of the Hartford nomogram | Lovering AM, Reeves DS J Antimicrob Chemother 2009 Nov;64(5):1117-8 |
| Pharmacokinetic evaluation of patients with major thermal injuries | Le Floch R, Arnould JF, Vinsonneau C, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Lovering AM Pathol Biol (Paris) 2009 Oct 23 & J Antimicrob Chemother 2009 Mar;63(3):553-9 |
| Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea | Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau C Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3176-84 |
| The effect of a modified posterior approach on blood flow to the femoral head during hip resurfacing | Khan A, Lovering AM, Bannister GC, Spencer RF, Kalap N Hip Int 2009 19, 52-7 |
| Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea | Kaye SB, Neal T, Nicholson S, Szkurlat J, Bamber S, Baddon AC, Anderson S, Seddon K, Dwyer N, Lovering AM, Smith G Invest Ophthalmol Vis Sci 2009 Jul;50(7):3176-84. Epub 2009 Feb 14 |
| Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations | Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM J Antimicrob Chemother 2009 May;63(5):1050-7 |
| Measurements of in vivo intra-articular gentamicin levels from antibiotic loaded articulating spacers in revision total knee replacement | Mutimer J, Gillespie G, Lovering AM, Porteous AJ Knee 2009 Jan;16(1):39-41 |
| An HPLC assay for daptomycin in serum | Tobin CM, Darville JM, Lovering AM, Macgowan AP J Antimicrob Chemother 2008 Dec;62(6):1462-3 |
| Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid | Darville JM, Lovering AM, MacGowan AP Int J Antimicrob Agents. 2007 Jul;30(1):30-3. Epub 2007 Apr 10 |
| Evidence of excessive concentrations of 5-flucytosine in children aged below 12years: a 12 year review of serum concentrations from a UK clinical assay reference laboratory | Soltani M, Tobin CM, Bowker KE, Sunderland, MacGowan AP, Lovering AM Int J Antimicrob Agents 2006 Dec;28(6):574-7 |
| Assay of ertapenem in human serum by High Performance Liquid Chromotgraphy | Soltani M, MacGowan AP, Lovering AM Int J Antimicrob Agents. 2006 Feb;27(2):165-7. Epub 2006 Jan 18 |
| The pharmacokinetics of linezolid in the non-inflamed human eye | JI Prydal, DR Jenkins, AM Lovering, A Watts Br J Opthalmol. 2005 Nov; 89, 1418-9 |
| Variability in the content of Indian generic ciprofloxacin eye drops | Weir RE, Zaidi FH, Charteris DG, Bunce C, Soltani M, Lovering AM Br J Ophthalmol. 2005 Sep;89(9):1094-6 |
| Residual antibiotics in allograft heart valve tissue samples following antibiotic disinfection | Leeming JP, Lovering AM, Hunt CJ J Hosp Infect 2005 Jul;60(3):231-4 |
| Pharmacokinetic studies of linezolid and teicoplanin in the critically ill | T Whitehouse, JA Cepeda, R Shulman, L Aarons, R Nalda-Molina, C Tobin, AP MacGowan, S Shaw, C Kibbler, M Singer, AP Wilson J Antimicrob Chemother 2005 Mar; 55, 333-40 |
| Resistance determinants in strains of Clostridium difficile from two geographically distinct populations | JS Bendle, PA James, PM Bennett, MB Avison, AP MacGowan, KM Al-Shafi Int J Antimicrob Agents. 2004 Dec; 24, 619-21 |
| Determination of Avilamycin A and B in pig faeces by solid phase extraction and reverse phase extraction | Sunderland J, Lovering AM, Tobin CM, MacGowan AP, Roe JM, Delsol AA Int J Antimicrob Agents 2004 Nov;24(5):511-4 |
| Gentamicin concentrations in diagnostic aspirates from 25 patients with hip and knee arthroplasties | Fletcher MD, Spencer RF, Langkamer VG, Lovering AM Acta Orthop Scand. 2004 Apr;75(2):173-6 |
| A reverse-phase HPLC assay for the simultaneous determination of enrofloxacin and ciprofloxacin in pig faeces | Sunderland J, Lovering AM, Tobin CM, MacGowan AP, Roe JM, Delsol AA Int J Antimicrob Agents. 2004 Apr;23(4):390-3 |
| Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin | J Desmond, AM Lovering, C Harle, T Djorevic, R Millner Eur J Card Surg 2003 May;23, 765-70 |
| Determination by HPLC of chlortetracycline in pig faeces | Sunderland J, Lovering AM, Tobin CM, MacGowan AP, Roe JM, Delsol AA J Antimicrob Chemother 2003 Apr; 51(4):1041-2 |
| A high performance liquid chromatography assay for linezolid in continuous ambulatory peritoneal dialysis fluid | CM Tobin, J Sunderland, AM Lovering, AP MacGowan J Antimicrob Chemother. 2003 51, 1041-2 |
| Variation in the disc content of ciprofloxacin susceptibility testing discs; its effect on the BSAC disc method | Darville JM, Lovering AM J Antimicrob Chemother. 2003 Feb; 51(2):465-7 |
| Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement | Lovering AM,Zhang J, Bannister GC, Lankaster BJ, Brown JH, Narendra G, MacGowan AP J Antimicrob Chemother 2002 Jul; 50(1):73-7 |
| Epidemiology and resource utilisation for patients hospitalized for lower reapiratory tract infection | Lovering AM, MacGowan AP, Anderson P, Irwin D Clin Microbiol Infect 2001 Dec;7(12):666-70 |
| Pharmacokinetics of once-a-day netilmicin (4.5mg/kg) in neonates | PE Gosden, KA Bedford, JJ Dixon, BD Speidel, AA Leaf, AP MacGowan J Chemother. 2001 Sep; 13: 270-6 |
| Difficullties in the assay of cefamandole highlight the importance of specific methodologies in pharmacokinetic studies | Zhang J, Lovering AM J Antimicrob Chemother. 2001 Jul;48(1):154-5 |
| The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone | Lovering AM, Walsh TR, Bannister GC, MacGowan AP J Antimicrob Chemother. 2001 Apr;47(4):483-6 |
| Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography | J Sunderland, CM Tobin, LO White, AP MacGowan, AJ Hedges J Antimicrob Chemother 2001 Mar; 47: 271-6 |
| Clinafloxacin serum concentrations in a patient on continuous veno-venous haemofiltration | ES Darley, AP MacGowan, RA Howe, CM Tobin J Antimicrob Chemother. 2000 Jun;45: 927-8 |
| Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentration and outcome | I Harding, AP MacGowan, LO White, ES Darley, V Reed J Antimicrob Chemother 2000 Jun; 45: 835-42 |
pD papers
|
Title |
Authors |
| Towards better antimicrobial susceptibility testing: impact of the Journal of Antimicrobial Chemotherapy. | Wootton M, MacGowan AP, Howe RA. J Antimicrob Chemother. 2017 Feb;72(2):323-329. |
| The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. | MacGowan A, Tomaselli S, Noel A, Bowker K. J Antimicrob Chemother. 2017 Mar 1;72(3):762-769. |
| Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. | Drusano GL, Louie A, MacGowan A, Hope W. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1183-93. |
| Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. | Drusano GL, Hope W, MacGowan A, Louie A. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1194-201. |
| The role of pharmacokinetics/pharmacodynamics in setting clincalm breakpoints; the EUCAST approach. | Mouton JW, Brown DF, Canton R, Apfaler P, Giske GC, Ivanova M, MacGowan AP, Rodloff AC, Soussy CJ, Steinbakk M, Kahlmeter G. Clin Microbial Infection. 2011 Oct |
| EUCAST rules expert rules in antimicrobial susceptibility testing | Leclercq R, Canton R, Brown DF, Giske GC, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter GMacGowan A, Clin Microbial Infection. 2011 Oct |
| Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective | Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J Drug Resist Updat. 2011 Apr;14(2):107-17 |
| Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection | MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K Antimicrob Agents Chemother. 2011 Jan 24 |
| The pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection | MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE Antimicrob Agents Chemother.2011 Feb;55(2):867-73 |
| Use of intravenous co-trimoxazole to treat bacterial infection: analysis of 50 treatment episodes | Barton E, MacGowan AP J Chemother. 2010 Aug;22(4):267-9 |
| Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility | Brown D, MacGowan A J Antimicrob Chemother. 2010 Feb;65(2):183-5 |
| Strain-to-strain variation on pharmacodynamic index a hitherto unconsidered factor in establishing antibiotic clinical breakpoints | MacGowan AP, Reynolds R, Noel AR, Bowker KE Antimicrob Agents Chemother. 2009 Dec;53(12):5181-4 |
| Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an vitro model of infection | Bowker KE, Noel AR, MacGowan AP Antimicrob Agents Chemother. 2009 Nov; 64(5): 1044-51 |
| Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model | Bowker KE, Noel AR, MacGowan AP Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3 |
| Tigecycline pharmacokinetic/pharmacodynamic update | MacGowan AP J Antimicrob Chemother 2008 Sep; 62 Suppl 1: 11-6 |
| Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an invitro pharmacokinetic model of Staphylococcus aureus infection | MacGowan AP, Bowker KE, Noel AR Antimicrob Agents Chemother. 2008 Apr;52(4):1401-6 |
| Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide intermediate Staphylococcus aureus (GISA) and heterogenous (h)GISA isolates | Wootton M, MacGowan AP, Walsh TR Antimicrob Agents Chemother. 2006 Dec;50(12):4195-7 |
| Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcylines | Agwuh K, MacGowan AP J Antimicrob Chemother. 2006 Dec, 58: 256-65 |
| Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system | Bowker KE, Noel AR, MacGowan AP J Antimicrob Chemother 2006 Oct; 58(4):802-5 |
| Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model | Noel AR, Bowker KE, MacGowan AP Antimicrob Agents Chemother. 2005 Oct;49 (10):4234-9 |
| Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta lactamases | Bowker KE, Noel AR, Walsh TR, Rogers CA, MacGowan AP Antimicrob Agents Chemother 2004 Nov;48(11):4482-4 |
| Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model | Bowker KE, Noel AR, Rogers CA, MacGowan AP Antimicrob Agents Chemother. 2004 Jul;48(7):2599-603 |
| In vitro studies on the impact of human serum on the antibacterial effect of faropenem | AP MacGowan, K Bowker J Chemother. 2004 Feb; 16, 23-9 |
| Mechanism of fluoroquinolone resistance is an important factor in determining antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model | MacGowan AP, Bowker KE Antimicrob Agents Chemother. 2003 Mar;47(4):1096-100 |
| Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes | HM Alloush, V Salisbury, RJ Lewis, AP MacGowan J Antimicrob Chemother. 2003 Sep; 52, 511-3 |
| Activities of moxifloxacin against, and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model | Bowker KE, Rogers CA, Holt HA, MacGowan AP Antimicrob Agents Chemother. 2003 Mar;47(3):1088-95 |
| The activity of vancomycin against heterogenous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored in an in vitro pharmacokinetic model | Turner J, Howe RA, Wootton M, Bowker KE, Salisbury V, Bennett PM, Walsh TR, MacGowan AP J Antimicrob Chemother 2001 Nov; 48(5):727-30 |
| Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model | MacGowan AP, Rogers CA, Wootton M, Holt HA, Bowker KE Antimicrob Agents Chemother. 2001 Oct;45(10):2916-21 |
Bcare (ARL) Contact Details
Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB
Telephone: 0117 4146269 or 0117 4146220
Fax: 0117 4146282
Email: arlenquiries@nbt.nhs.uk